Summary Age-related macular degeneration (AMD) is the leading cause of blindness in patients over 50 years of age in developed countries. It is estimated that the projected number of people with AMD will be 196 million worldwide by the year 2020, increasing to 288 million by 2040. Of these patients, 10–20% suffering from the fast progressing neovascular form of the disease (nAMD) account for 90% of all cases of severe vision loss. In fact, AMD is responsible for 8.7% of all cases of blindness worldwide. These numbers indicate the substantial burden of the disease. The WHO estimates that 246 million people worldwide currently have low vision and 39 million are blind. A literature (Medline) and Internet research was performed to better understand the prevalence of AMD and how health care could be prepared to cope with it in the future. In 2015, there were 90,010 intravitreal injections (IVI) in Austrian hospitals and primary care units. In 2016, this number rose to >100,000 IVI as the applications increase by approx. 15–20% every year. Since health insurances do not refund IVI in primary care, these services are channeled toward clinical wards, causing overcrowded waiting rooms and dissatisfied patients. Despite this high number of IVI in Austria, real-life data show that the number of IVI given today is not sufficient to keep visual acuity on a steady level. Therefore, new and long-acting treatment options are needed to end the burden for clinics and patients and to increase treatment efficiency by simplified protocols. Herein, a potential new gene-therapeutic approach using nonviral vectors and somatic pigment epithelial cells to overcome the imbalance of pigment epithelium-derived factor and vascular endothelial growth factor in nAMD is described.
blind               0.9999987821029803^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Blindness             

vectors                       0.9905735767443895^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Vector_(epidemiology) 

epithelial cells              0.9999999999693046^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Epithelium            

disease                       0.9999872272400715^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Disease               

pigment                       0.42444616943462476^^http://www.w3.org/2001/XMLSchema#double          http://dbpedia.org/resource/Melanocyte            

The WHO                       1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/The_Who               

primary care                  0.8179122540728315^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Primary_health_care   

Austria                       0.999999591450516^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Austria               

disease                       0.9999872272400715^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Disease               

AMD                           0.9999963917331639^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Advanced_Micro_Devices

IVI                           0.9999999777767246^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/In_car_entertainment  

visual acuity                 1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Visual_acuity         

vision loss                   0.9999999999417923^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Vision_loss           

Medline                       1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/MEDLINE               

IVI                           0.9999999777767246^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/In_car_entertainment  

protocols                     0.9970801982778564^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Medical_guideline     

AMD                           0.9999963917331639^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Advanced_Micro_Devices

blindness                     0.9999997001255446^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Blindness             

AMD                           0.9999963917331639^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Advanced_Micro_Devices

neovascular                   0.8679687199313384^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/neovascularization    

nAMD                          0.9999999996930455^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/NAMD                  

intravitreal                  1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Intravitreal_administration

somatic                       0.9992435589414926^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Somatic               

prevalence                    1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Prevalence            

Internet                      0.9999999898454917^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Internet              

IVI                           0.9999999777767246^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/In_car_entertainment  

Age-related macular degeneration1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Macular_degeneration  

developed countries           0.9999999996521183^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Developed_country     

hospitals                     1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Hospital              

literature                    0.9999993323196987^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Literature            

health care                   0.9999999987646788^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Health_care           

health                        0.9638295229888048^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Health_care           

Austrian                      0.9999980797217879^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Austria               

IVI                           0.9999999777767246^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/In_car_entertainment  

nAMD                          0.9999999996930455^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/NAMD                  

vascular endothelial growth factor1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Vascular_endothelial_growth_factor

primary care                  0.8179122540728315^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Primary_health_care   

AMD                           0.9999963917331639^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Advanced_Micro_Devices

IVI                           0.9999999777767246^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/In_car_entertainment  

blindness                     0.9999997001255446^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Blindness             

wards                         1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Hospital              

pigment                       0.42444616943462476^^http://www.w3.org/2001/XMLSchema#double          http://dbpedia.org/resource/Melanocyte            

